Changing the Treatment Landscape for Prostate Cancer:
Moving Towards Improved Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2022 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from March 1, 2023 to March 1, 2024
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AstraZeneca, Merck Sharp & Dohme LLC, and Sanofi

Description:
Prostate cancer is the most diagnosed non-cutaneous cancer in men in the United States (US) and remains the second leading cause of cancer deaths among American men, with an estimated 248,530 new cases diagnosed last year. Prostate cancer deaths are typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. About 40 percent of these patients have prostate cancer that is also associated with a rising prostate-specific antigen (PSA) level that has not spread to other parts of the body. The danger that can occur, if not caught early, is that 33% of those men could have the cancer spread to other parts of the body. With guidelines continuing to be updated, the novel insights in the current and emerging therapeutic agents hope to continue to improve patient prognosis and quality of life by delaying metastatic spread and the need for highly toxic chemotherapeutic agents. Advances in the past few years have resulted in the investigations of several novel targeted therapies, including androgen receptor inhibitor (ARI) targeting agents, antineoplastic agent and gonadotropin releasing hormone agonist, tyrosine kinase inhibitors (TKIs), antiangiogenic agents, endothelin receptor antagonists, anti-apoptotic protein inhibitors, and PARP-1 inhibitors. This session will provide participants with education on the advances in the treatment and management of prostate cancer. In the last few years, advances in the treatment of prostate cancer have greatly improved with new updates in current and emerging treatments.


Upon completion of this activity, participants will be able to:

  • Implement guideline-recommended management strategies for patients with prostate cancer

  • Discuss current diagnostic methods that will properly identify prostate cancer patients, including genetic testing guidelines to determine appropriate patient selection for optimal management

  • Evaluate the latest safety and efficacy data on current and emerging therapies for prostate cancer

  • Explore recent data from clinical trials regarding the use of mono and combination therapy

  • Incorporate evidence-based benefit-risk assessment and utilize shared decision-making in the development of individualized treatment plans

  • Assess managed care considerations to facilitate optimal use of novel combination options in prostate cancer

     

Faculty: Matthew R. Smith, M.D., Ph.D.
Professor of Medicine, Harvard Medical School
Director, MGH Genitourinary Malignancies Program

Disclosure:

(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Smith has served as a consultant for Astellas, Bayer, Janssen, Lilly, and Pfizer. He has received grant/research support from Bayer, Janssen, and Lilly. His presentation has been reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AstraZeneca, Merck Sharp & Dohme LLC, and Sanofi


NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue